# Jane B. Trepel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jane-b-trepel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,969 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 88 |
| i10-index | 253 |
| Last Known Institution | National Cancer Institute |
| OpenAlex ID | https://openalex.org/A5040289016 |
| ORCID iD | https://orcid.org/0000-0002-7681-6554 |
| Works | 659 |

## Researcher papers

- [MGMT Status as a Clinical Biomarker in Glioblastoma](https://scholariq.org/papers/mgmt-status-as-a-clinical-biomarker-in-glioblastoma/)
- [Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial](https://scholariq.org/papers/sunitinib-in-patients-with-chemotherapy-refractory-thymoma-and-thymic-carcinoma/)
- [Hypoxia-Inducible Factor-1 (HIF-1) Up-Regulates Adrenomedullin Expression in Human Tumor Cell Lines during Oxygen Deprivation: A Possible Promotion Mechanism of Carcinogenesis](https://scholariq.org/papers/hypoxia-inducible-factor-1-hif-1-up-regulates-adrenomedullin-expression-in-human/)
- [Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors](https://scholariq.org/papers/phase-ii-study-of-belinostat-in-patients-with-recurrent-or-refractory-advanced/)
- [Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study](https://scholariq.org/papers/durvalumab-in-combination-with-olaparib-in-patients-with-relapsed-sclc-results/)
- [Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress](https://scholariq.org/papers/therapeutic-targeting-of-atr-yields-durable-regressions-in-small-cell-lung/)
- [Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors](https://scholariq.org/papers/phase-i-study-of-atr-inhibitor-m6620-in-combination-with-topotecan-in-patients/)
- [Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer](https://scholariq.org/papers/notch-signaling-and-efficacy-of-pd-1-pd-l1-blockade-in-relapsed-small-cell-lung/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Heat shock proteins research](https://scholariq.org/topics/heat-shock-proteins-research/)
- [Histone Deacetylase Inhibitors Research](https://scholariq.org/topics/histone-deacetylase-inhibitors-research/)
- [Computational Drug Discovery Methods](https://scholariq.org/topics/computational-drug-discovery-methods/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Researcher university

- [National Cancer Institute](https://scholariq.org/institutions/national-cancer-institute-3/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.